| Component: (Network and Table) | |
|---|---|
| Network | 0140 - Statement - Consolidated Statements of Cash Flows (http://accentia.net/2011-06-30/role/StatementCondensedConsolidatedStatementsOfCashFlows) |
| Table | (Implied) |
| Reporting Entity [Axis] | 0001310094 (http://www.sec.gov/CIK) |
| Consolidated Statements of Cash Flows [Abstract] | Period [Axis] | |
|---|---|---|
2011-10-01 - 2012-09-30 | 2010-10-01 - 2011-09-30 | |
Consolidated Statements of Cash Flows [Abstract] | ||
Cash flows from (used in) operating activities: | ||
Net loss | (9,187,765) | (15,653,041) |
Adjustments to reconcile net loss to net cash flows from operating activities before reorganization items: | ||
Depreciation | 147,285 | 102,976 |
Amortization | 102,555 | 458,790 |
Share-based compensation | 3,840,070 | 16,306,738 |
Accretion of debt discounts | 3,187,571 | 1,926,550 |
Accretion of capitalized finance costs | 99,723 | 967,338 |
Derivative gain | (1,416,098) | (1,058,012) |
Gain on conversion of debt | (386,582) | |
Gain on the sale of assets, discontinued operations | (3,998,105) | |
Gain on settlement | (827,196) | |
Issuance of common stock shares for interest expense | 316,038 | 434,415 |
Issuance of common stock warrants for finance costs | 1,247,582 | |
Issuance of common stock shares for services | 2,800 | 40,500 |
Increase (decrease) in cash resulting from changes in: | ||
Accounts receivable | 1,101,836 | (35,144) |
Inventories | 132,036 | (114,912) |
Unbilled receivables | (238,632) | 105,616 |
Prepaid expenses and other current assets | (49,244) | 6,874 |
Other assets | 75,077 | (483,541) |
Assets from discontinued operations | 436,956 | (178,213) |
Accounts payable | 465,854 | 480,176 |
Accrued expenses | 4,207,073 | 3,157,337 |
Unearned revenues | 394,173 | |
Customer deposits | (115,554) | (8,619) |
Accrued income taxes | 609,937 | |
Other liabilities | 12,384 | |
Liabilities from discontinued operations | (361,319) | 65,782 |
Net cash flows from operating activities before reorganization items | (621,931) | 6,941,996 |
Reorganization items: | ||
Gain on reorganization plan | (5,687,881) | (12,732,454) |
Decrease increase in accrued professional fees | (325,333) | |
Total recognition | (5,687,881) | (13,057,787) |
Net cash used in operating activities | (6,309,812) | (6,115,791) |
Cash flows from investing activities: | ||
Acquisition of property, plant and equipment | (97,998) | (789,065) |
Proceeds from the sale of assets | 5,500,000 | |
Net cash provided by (used in) investing activities | 5,402,002 | (789,065) |
Cash flows from financing activities: | ||
Proceeds from notes payable, related party | 3,500,000 | 2,250,000 |
Proceeds from long-term notes | 7,353,000 | |
Proceeds private placement of common stock | 625,000 | |
Proceeds from the exercise of stock options | 35,509 | 6,000 |
Proceeds from the exercise of stock warrants | 144,583 | |
Payments on notes payable and long-term debt | (3,676,945) | (1,718,596) |
Payment of deferred financing costs | (1,059,587) | |
Payments made to related parties | (30,459) | |
Payment on related party notes | (11,709) | (33,414) |
Net cash flows from financing activities | 616,438 | 6,766,944 |
Net change in cash and cash equivalents | (291,372) | (137,912) |
Cash and cash equivalents at beginning of period | 420,540 | 558,452 |
Cash and cash equivalents at end of period | 129,168 | 420,540 |
Supplemental cash flow information: | ||
Cash paid for interest | 572,181 | 236,841 |
Supplemental disclosure of non-cash financing activity: | ||
Biovest warrants issued | 1,247,582 | |
Accentia warrants issued | 217,035 | 696,049 |
Reclassification of derivative to equity | 35,457,696 | |
Reclassification of beneficial conversion feature, Accentia | 815,200 | 598,069 |
Reclassification of beneficial conversion feature, Biovest | 2,138,789 | |
Accentia shares issued on the Effective Date upon the conversion of debt | 13,709,018 | |
Accentia shares issued upon the conversion of promissory notes | 6,506,859 | 2,612,766 |
Accentia shares issued in resolution of disputed claims | 740,800 | 420,641 |
Biovest shares issued on effective date upon the conversion of debt | 6,631,156 | |
Biovest shares issued upon the conversion of debt | 1,135,199 | 1,383,724 |
Accentia owned Biovest shares tendered in payment of Accentia debt | 2,008,114 | 932,941 |
Purchase of equipment with promissory notes | 220,408 | |